Patents Assigned to Amarin Technologies S.A.
  • Publication number: 20140221942
    Abstract: The present invention pertains generally to the field of transdermal drug delivery. More specifically, the invention relates to a device for the transdermal delivery of an alkaline pharmaceutically active compound that is susceptible to degradation in its free base form (e.g., rivastigmine) that comprises an adhesive matrix layer, a backing layer and a release or protective layer, wherein the adhesive matrix layer comprises said pharmaceutically active compound, triethylcitrate and hydrochloric acid. The invention also relates to methods of preparing such devices.
    Type: Application
    Filed: August 21, 2012
    Publication date: August 7, 2014
    Applicant: AMARIN TECHNOLOGIES S.A.
    Inventors: Alejandro Fabio Scasso, Francisco Jose Evaristo Stefano
  • Patent number: 8017146
    Abstract: A device for the transdermal delivery of a pharmacologically active substance has first and second superimposed mutually contacting adhesive layers (2, 3). The first layer (3) is in use brought into contact with the skin. The active substance is dissolved in both layers, the affinity of the first layer for the active substance being between about 1.15 and about 10 times lower than that of the second layer. The percent saturation of the active substance in both the layers is the same and is less than 100%. The first layer has a greater thickness than the second layer. The device is simple and can provide stable delivery over a long period.
    Type: Grant
    Filed: May 15, 2003
    Date of Patent: September 13, 2011
    Assignee: Amarin Technologies S.A.
    Inventors: Francisco Jose Evaristo Stefano, Alejandro Fabio Scasso
  • Patent number: 6465005
    Abstract: A steroid is used as an additive in manufacture of a transdermal drug delivery device, to act as a crystallization inhibitor inhibiting crystallization, during storage of the device, of an active drug in the form of a hormone which has a pharmaceutical or physiological effect in use of the device. The crystallization-inhibiting steroid is present in the device in an amount insufficient to provide significant pharmaceutical or physiological effect in use of the device.
    Type: Grant
    Filed: May 17, 2000
    Date of Patent: October 15, 2002
    Assignee: Amarin Technologies S.A.
    Inventors: Fabián Isaac Biali, Alejandro Fabio Scasso, Francisco José Evaristo Stefano